AngioDynamics, Inc. $ANGO Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 19.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 237,080 shares of the medical instruments supplier’s stock after selling 56,145 shares during the quarter. Assenagon Asset Management S.A. owned 0.58% of AngioDynamics worth $3,044,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State of Alaska Department of Revenue acquired a new stake in AngioDynamics in the third quarter valued at $25,000. Washington Trust Advisors Inc. purchased a new stake in shares of AngioDynamics during the 3rd quarter worth $27,000. State of Wyoming acquired a new position in shares of AngioDynamics during the 2nd quarter worth $31,000. Russell Investments Group Ltd. grew its stake in shares of AngioDynamics by 329.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 3,213 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in shares of AngioDynamics by 359.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 4,268 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Stock Down 0.3%

Shares of ANGO stock opened at $10.87 on Tuesday. AngioDynamics, Inc. has a fifty-two week low of $8.36 and a fifty-two week high of $13.99. The stock has a market cap of $448.06 million, a P/E ratio of -16.22 and a beta of 0.48. The business has a fifty day simple moving average of $10.81 and a 200-day simple moving average of $11.54.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ANGO shares. Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st. Finally, Zacks Research upgraded shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.